Pfizer will pay $1.25 billion upfront to license an experimental cancer drug out of China, in a deal that underscores multinational drugmakers’ growing enthusiasm for Chinese biotech innovation.
www.bloomberg.com
#Pfizer #Licenses #3SBio #Cancer #Drug #Record #Billion
Pfizer Licenses 3SBio Cancer Drug for Record $1.2 Billion
